A Universal Biomarkerfor cancer
Travera is using a breakthrough technology to measure which cancer drugs work against each individual’s unique cancer cells. We are developing a universal biomarker for enabling oncologists to quickly determine which drugs to prescribe based on the actual responses of their patients’ tumor cells to candidate drugs.
Travera was founded in 2017 to commercialize a breakthrough measurement technology and biomarker developed in the Manalis Laboratory in the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology (MIT).
What’s New at Travera
MEDFORD, MASSACHUSETTS – July 15, 2021 – Travera, Inc. has announced that it has recently closed a $5.5 million Series A Extension. The financing was led by Khosla Ventures and joined by existing investor Horizons Ventures and a new investor in the company, MSA...
MEDFORD, MASSACHUSETTS – January 4, 2021 – Travera, LLC has announced that it has moved from its 1,000 sq.ft. laboratory in Cambridge, Massachusetts to a 3,500 sq.ft. lab in Medford, Massachusetts. This new location remains near the Massachusetts Institute of...
CAMBRIDGE, MASSACHUSETTS - OCTOBER 8, 2020 – Travera, LLC has been awarded a National Science Foundation (NSF) Phase II Small Business Innovation Research (SBIR) grant in the amount of $1 million to conduct research and development (R&D) of the company's suspended...
Read our white paper
Travera’s solution is to try drugs on the OUTSIDE of the patient rather than INSIDE. That is, remove some of the cancer cells from the patient and apply the drugs to these removed (“ex vivo”) cancer cells. We can then try many different cancer drugs (in very small quantities) against these cancer cells. This approach completely eliminates toxicity, dramatically reduces the cost (because we only need enough drug to treat a few cells, not a whole person), and only takes a couple of days.